Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease
NCT ID: NCT03330470
Last Updated: 2025-05-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
26 participants
INTERVENTIONAL
2017-01-01
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Movement Improves Brain Health and Cognition in Parkinson's Disease
NCT07299279
Exploring the Effects of Exercise on Memory and Cognition in Parkinson´s Disease
NCT06580977
Effects of Physical Activity on the Brain in Parkinson's Disease (PD)
NCT01741584
Exercise to Improve Sleep in Parkinson's Disease
NCT05644327
Effects of Exercise on Long-Range Autocorrelations in Parkinson's Disease
NCT02419768
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
exercise and carnosine supplementation
exercise: participants will be subjected to 4 months of supervised exercise intervention carnosine supplementation: participants will be instructed to take carnosine 2 times daily
exercise
participants will be subjected to 4 months supervised exercise intervention
carnosine supplementation
participants will be instructed to take carnosine 2 times daily
exercise and supplementation with placebo
exercise: participants will be subjected to 4 months of supervised exercise intervention supplementation with placebo: participants will be instructed to take placebo 2 times daily
exercise
participants will be subjected to 4 months supervised exercise intervention
supplementation with placebo
participants will be instructed to take placebo 2 times daily
stretching controls and carnosine supplementation
stretching controls: participants will be subjected to 4 months of supervised stretching program carnosine supplementation: participants will be instructed to take carnosine 2 times daily
carnosine supplementation
participants will be instructed to take carnosine 2 times daily
stretching
participants will be subjected to 4 months supervised stretching program
stretching controls and supplementation with placebo
stretching controls: participants will be subjected to 4 months of supervised stretching program supplementation with placebo: participants will be instructed to take placebo 2 times daily
stretching
participants will be subjected to 4 months supervised stretching program
supplementation with placebo
participants will be instructed to take placebo 2 times daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
exercise
participants will be subjected to 4 months supervised exercise intervention
carnosine supplementation
participants will be instructed to take carnosine 2 times daily
stretching
participants will be subjected to 4 months supervised stretching program
supplementation with placebo
participants will be instructed to take placebo 2 times daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 55 - 80 years
* Presence of Subjective Cognitive Impairment (SCI), Mild Cognitive Impairment (MCI) or early stage of Parkinson's Disease (Hoehn-Yahr 1st-2nd stage), assessed by experienced neurologist
Exclusion Criteria
* Lack of compliance
55 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Comenius University
OTHER
University Hospital Bratislava
OTHER
National Cheng Kung University
OTHER
Slovak Academy of Sciences
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Barbara Ukropcová, MD, PhD
Prof. MD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Turčáni, Prof., MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Bratislava, Comenius University, Bratislava,
Peter Valkovič, Prof., MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Bratislava, Comenius University, Bratislava,
Barbara Ukropcová, Assoc. Prof., MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Biomedical Research Center, Slovak Academy of Sciences,
Jozef Ukropec, DrSc, PhD
Role: PRINCIPAL_INVESTIGATOR
Biomedical Research Center, Slovak Academy of Sciences,
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Bratislava, Comenius University
Bratislava, , Slovakia
Biomedical Research Center, Slovak Academy of Sciences
Bratislava, , Slovakia
Laboratory of Cognitive Neurophysiology, Institute of Physical Education, Health & Leisure Studies, National Cheng Kung University
Tainan City, Tainan, Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-0253
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.